Interv Akut Kardiol. 2019;18(4):236-237
The MARINER Study
- 1 I. interní kardioangiologická klinika, FN u sv. Anny, Brno
- 2 Lékařská fakulta Masarykovy univerzity, Brno
The Mariner study aimed to ascertain whether prolonged administration of rivaroxaban for a period of several weeks had any importance for thromboprophylaxis. The aim was to show efficacy as well as safety of prolonged prophylactic administration of rivaroxaban in a population at risk. The primary endpoint was a composite of deep vein thrombosis and nonfatal pulmonary embolism or death from thromboembolic disease. The primary safety endpoint was major bleeding. Rivaroxaban, when administered preventively for 45 days, failed to significantly reduce the composite endpoint of venous fatal or nonfatal thromboembolism compared with placebo. The rate of major bleeding in the entire study was very low.
Keywords: rivaroxaban, thromboembolism, prophylaxis, bleeding
Published: December 1, 2019 Show citation
